These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 17471167)
1. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. Johnson BD; Jing W; Orentas RJ J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167 [TBL] [Abstract][Full Text] [Related]
2. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Xia G; He J; Zhang Z; Leventhal JR Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271 [TBL] [Abstract][Full Text] [Related]
3. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Saha A; Chatterjee SK Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858 [TBL] [Abstract][Full Text] [Related]
4. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774 [TBL] [Abstract][Full Text] [Related]
5. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. Setiady YY; Coccia JA; Park PU Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297 [TBL] [Abstract][Full Text] [Related]
6. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721 [TBL] [Abstract][Full Text] [Related]
7. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483 [TBL] [Abstract][Full Text] [Related]
8. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805 [TBL] [Abstract][Full Text] [Related]
10. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy. Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386 [TBL] [Abstract][Full Text] [Related]
11. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells. Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. Cao Q; Wang L; Du F; Sheng H; Zhang Y; Wu J; Shen B; Shen T; Zhang J; Li D; Li N Cell Res; 2007 Jul; 17(7):627-37. PubMed ID: 17563757 [TBL] [Abstract][Full Text] [Related]
13. [Combination of CD4+ CD25+ regulatory T cell and costimulatory pathway blockade inhibits acute rejection after liver transplantation: experiment with rats]. Shi LB; Zhang HW; Peng CH Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(14):942-6. PubMed ID: 17650415 [TBL] [Abstract][Full Text] [Related]
14. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720 [TBL] [Abstract][Full Text] [Related]
15. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine]. Ma J; Wang YL; Hu HM; Fox BA; Si LS Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138 [TBL] [Abstract][Full Text] [Related]
16. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322 [TBL] [Abstract][Full Text] [Related]
17. Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61. McNeill A; Spittle E; Bäckström BT Scand J Immunol; 2007 Jan; 65(1):63-9. PubMed ID: 17212768 [TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032 [TBL] [Abstract][Full Text] [Related]
19. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice. Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320 [TBL] [Abstract][Full Text] [Related]
20. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection. He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]